1877 Stock Overview A biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add noteShanghai Junshi Biosciences Co., Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Shanghai Junshi Biosciences Historical stock prices Current Share Price HK$11.54 52 Week High HK$21.70 52 Week Low HK$9.17 Beta 0.39 1 Month Change 6.85% 3 Month Change -18.16% 1 Year Change -4.79% 3 Year Change -74.07% 5 Year Change n/a Change since IPO -87.16%
Recent News & Updates
Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial Feb 05 Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended 31 December 2024
Shanghai Junshi Biosciences Co., Ltd. Receives the Notice of Approval for Supplemental Issued by the National Medical Products Administration Jan 10
Shanghai Junshi Biosciences Co., Ltd.'s JS212 Injection Receives the Acceptance Notice for Theinvestigational New Drug Application Jan 08
Shanghai Junshi Biosciences Co., Ltd. Receives Conditional Approval from the National Medical Products Administration Jan 06
Shanghai Junshi Biosciences Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025 Dec 27 See more updates
Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial Feb 05 Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended 31 December 2024
Shanghai Junshi Biosciences Co., Ltd. Receives the Notice of Approval for Supplemental Issued by the National Medical Products Administration Jan 10
Shanghai Junshi Biosciences Co., Ltd.'s JS212 Injection Receives the Acceptance Notice for Theinvestigational New Drug Application Jan 08
Shanghai Junshi Biosciences Co., Ltd. Receives Conditional Approval from the National Medical Products Administration Jan 06
Shanghai Junshi Biosciences Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025 Dec 27
Shanghai Junshi Biosciences Co., Ltd. Announces Board and Committee Changes Dec 20 Shanghai Junshi Biosciences Co., Ltd.(SHSE:688180) dropped from SSE 180 Index
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address of Principal Place of Business in Hong Kong Nov 30 Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address of Principal Place of Business in Hong Kong
Third quarter 2024 earnings released: CN¥0.29 loss per share (vs CN¥0.42 loss in 3Q 2023) Oct 30
Shanghai Junshi Biosciences Co., Ltd. Announces the Approval of New Drug Application for Ongericimab Injection Oct 14
Shanghai Junshi Biosciences Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Sep 30
Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial Sep 26
Shanghai Junshi Biosciences Co., Ltd. Receives Approval by the European Commission for Marketing of Toripalimab Sep 24
Second quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.46 loss in 2Q 2023) Aug 31
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma Aug 13
Shanghai Junshi Biosciences Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug Application for WJ47156 Tablets Jul 09
Shanghai Junshi Biosciences Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024 Jun 28
Shanghai Junshi Biosciences Co., Ltd. Receives the Drug Registration Certificate Issued by the National Medical Products Administration Jun 26
Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes Jun 24
Shanghai Junshi Biosciences Co., Ltd Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer Jun 19
Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration Jun 14
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma Jun 13
Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 21, 2024 May 31
First quarter 2024 earnings released Apr 30 Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region
No longer forecast to breakeven Apr 17
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer Apr 10
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection Apr 03
Shanghai Junshi Biosciences Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Mar 30
Full year 2023 earnings released: CN¥2.32 loss per share (vs CN¥2.60 loss in FY 2022) Mar 30
Full year 2023 earnings released: CN¥2.28 loss per share (vs CN¥2.60 loss in FY 2022) Feb 24
Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023 Feb 01
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer Jan 13 Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board
Shanghai Junshi Biosciences Co., Ltd. Announces Publication of Results from Toripalimab, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine Jan 10
Shanghai Junshi Biosciences Co., Ltd. Announces New Indications of TUOYI and MINDEWEI Included in New Edition of National Reimbursement Drug List Dec 13 Shanghai Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia's TGA
Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association Nov 29
New minor risk - Profitability Nov 09
Third quarter 2023 earnings released: CN¥0.42 loss per share (vs CN¥0.75 loss in 3Q 2022) Oct 29
Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Oct 28
Shanghai Junshi Biosciences Co., Ltd. Directors Appointments Oct 21
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab for the First-Line Treatment of Melanoma Met Primary Endpoint Sep 26
Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares. Sep 12 Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Notice of Approval for Clinical Trial
Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director Aug 31
Second quarter 2023 earnings released: CN¥0.46 loss per share (vs CN¥0.56 loss in 2Q 2022) Aug 31
Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares. Aug 28
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-Linetreatment of Advanced RCC Jul 12
Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes Jul 01
Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Acceptance Notice For the Investigational New Drug Application Jun 20 Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 30, 2023
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple - Negative Breast Cancer May 24
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Chemotherapy for the First-Line Treatment of ES-SCLC Met Primary Endpoint May 08
First quarter 2023 earnings released: CN¥0.55 loss per share (vs CN¥0.44 loss in 1Q 2022) Apr 30
Now 21% undervalued after recent price drop Apr 11
Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02 Feb 16
Shanghai Junshi Biosciences Co., Ltd. Announces JS401 Injection Receival the Acceptance Notice for The Investigational New Drug Application Feb 01 Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2022 Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of NDA for VV116 in China
Now 26% undervalued Jan 03
Shanghai Junshi Biosciences Co., Ltd, Shanghai Juntop Biosciences Co., Ltd. and Vigonvita Life Sciences Co., Ltd. Announce Progress of the Clinical Studies of VV116 Jan 03
Shanghai Junshi Biosciences Co., Ltd. Receives Acceptance Notice for the Investigational New Drug Application Dec 31
Shanghai Junshi Biosciences Co., Ltd Announces Nejm Publication of Results of Phase 3 Study of Vv116 Versus Paxlovid for Adults At High Risk for Progression to Severe Covid-19 Dec 30
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Dec 26
Shanghai Junshi Biosciences Co., Ltd. Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting Dec 13
Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes Dec 10
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Marketing Authorization Application of Toripalimab Dec 06
Shanghai Junshi Biosciences Co., Ltd Submits Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency Nov 25
Shanghai Junshi Biosciences Co., Ltd. Announces Receiving the Notice of Approval for Supplemental Drug Application Issued by the National Medical Products Administration Nov 22
No longer forecast to breakeven Nov 16
Shanghai Junshi Biosciences Co., Ltd. Announces Submission of A Marketing Authorization Application to the European Medicines Agency for Toripalimab Nov 15
Shanghai Junshi Biosciences Co., Ltd. Receives the Notice of Approval for Clinical Trial Issued by the National Medical Products Administration Oct 31
Third quarter 2022 earnings released: CN¥0.75 loss per share (vs CN¥0.50 loss in 3Q 2021) Oct 31
Shanghai Junshi Biosciences Co., Ltd. to Report Nine Months, 2022 Results on Oct 28, 2022 Oct 19
Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology Oct 13
Shanghai Junshi Biosciences Co., Ltd Receives NMPA Approval of sNDA for Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small Cell Lung Cancer Sep 21
Forecast breakeven date pushed back to 2024 Sep 03
Second quarter 2022 earnings released: CN¥0.57 loss per share (vs CN¥0.37 loss in 2Q 2021) Sep 01 Suzhou Junjing Biomedical Technology Co., Ltd. Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)
Shanghai Junshi Biosciences Co., Ltd. to Report Q2, 2022 Results on Aug 30, 2022 Aug 18 Shareholder Returns 1877 HK Biotechs HK Market 7D 4.9% 4.5% 2.3% 1Y -4.8% 14.6% 24.5%
See full shareholder returns
Return vs Market: 1877 underperformed the Hong Kong Market which returned 24.5% over the past year.
Price Volatility Is 1877's price volatile compared to industry and market? 1877 volatility 1877 Average Weekly Movement 6.1% Biotechs Industry Average Movement 7.9% Market Average Movement 6.4% 10% most volatile stocks in HK Market 13.7% 10% least volatile stocks in HK Market 3.0%
Stable Share Price: 1877 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1877's weekly volatility (6%) has been stable over the past year.
About the Company Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Show more Shanghai Junshi Biosciences Co., Ltd. Fundamentals Summary How do Shanghai Junshi Biosciences's earnings and revenue compare to its market cap? 1877 fundamental statistics Market cap HK$24.84b Earnings (TTM ) -HK$1.93b Revenue (TTM ) HK$1.91b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1877 income statement (TTM ) Revenue CN¥1.79b Cost of Revenue CN¥622.89m Gross Profit CN¥1.16b Other Expenses CN¥2.97b Earnings -CN¥1.80b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 28, 2025
Earnings per share (EPS) -1.83 Gross Margin 65.15% Net Profit Margin -100.90% Debt/Equity Ratio 43.8%
How did 1877 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/07 19:47 End of Day Share Price 2025/02/07 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Shanghai Junshi Biosciences Co., Ltd. is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Tan Huan Gan Citic Securities Co., Ltd. Congmin Yuan Citic Securities Co., Ltd. Muk Tsz Yung Citigroup Inc
Show 14 more analysts